Sarcopenia and rheumatoid arthritis
Background. Nowadays in the field of syndromes and diseases associated with age, scientists focus especial attention on the problem of sarcopenia, which combines an increased risk of falls, deterioration of life quality, impaired functional activity, reduced life expectancy and increased mortality of patients. In 2016, sarcopenia has been included in the International Classification of Diseases. There are the primary and secondary forms of sarcopenia. This article presents the reference data and results of our own studies on sarcopenia in the rheumatoid arthritis patients. The aim of this study was to evaluate the bone mineral density, lean mass and frequency of prescarcopenia in patients with rheumatoid arthritis. Materials and methods. 461 women aged 40–87 years (age 57.17 ± 0.71 years) were examined, among them 71 patients with rheumatoid arthritis and 390 controls. We conducted the clinical and laboratory examination (erythrocyte sedimentation rate and Creactive protein level in serum). Pain intensity was evaluated by the visual analogue scale, the quality of life – by the HAQ questionnaire. Lean mass, bone mineral density were measured by the Xray absorptiometry (Prodigy, GEHC Lunar, Madison, WI, USA). Presarcopenia (first stage of sarcopenia) was determined when an appendicular lean mass index was less than 5.72 kg/m2 (V.V. Povoroznyuk, N.I. Dzerovich, 2016). Statistical analysis was conducted using the "Statistica 6.0" software. Results. Patients with rheumatoid arthritis had a significantly lower femoral neck mineral density (p = 0.002), lean mass of the total body (p = 0.01) and appendicular lean mass (p < 0.01). The frequency of presarcopenia in women with rheumatoid arthritis was 49 %, in the control group — 18 %. Conclusions. Patients with rheumatoid arthritis had not only bone tissue, but also skeletal muscle tissue disorders, resulting in a significant deterioration of functional capacity and quality of life. Given the significant medical and social significance of the problem, further studies into the mechanisms of pathogenesis, development of diagnostic methods, prevention and treatment of sarcopenia in patients with rheumatoid arthritis are required.
Rosenberg IH. Sarcopenia: origins and clinical relevance. J Nutr. 1997 May;127(5 Suppl):990S-991S. doi: 10.1093/jn/127.5.990S.
Burton LA, Sumukadas D. Optimal management of sarcopenia. Clin Interv Aging. 2010 Sep 7;5:217-28.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010 Jul;39(4):412-23. doi: 10.1093/ageing/afq034.
Cruz-Jentoft AJ, Landi F, Schneider SM, et al. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). Age Ageing. 2014 Nov;43(6):748-59. doi: 10.1093/ageing/afu115.
Di Monaco M, Castiglioni C, Vallero F, Di Monaco R, Tappero R. Appendicular lean mass does not mediate the significant association between vitamin D status and functional outcome in hip-fracture women. Arch Phys Med Rehabil. 2011 Feb;92(2):271-6. doi: 10.1016/j.apmr.2010.09.028.
Landi F, Cruz-Jentoft AJ, Liperoti R, et al. Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study. Age Ageing. 2013 Mar;42(2):203-9. doi: 10.1093/ageing/afs194.
Morley JE., Anker SD., Evans WJ. Cachexia and aging: an update based on the Fourth International Cachexia Meeting. J Nutr Health Aging. 2009 Jan;13(1):47-55.
Volpato S, Bianchi L, Cherubini A, et al. Prevalence and clinical correlates of sarcopenia in community-dwelling older people: application of the EWGSOP definition and diagnostic algorithm. J Gerontol A Biol Sci Med Sci. 2014 Apr;69(4):438-46. doi: 10.1093/gerona/glt149.
Anker SD, Morley JE, von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):512-514. doi: 10.1002/jcsm.12147.
Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169.
Povoroznyuk V, Binkley N, Dzerovych N, Povoroznyuk R. Sarkopeniya [Sarcopenia]. Kyiv; 2016. 180 p. (In Ukrainian).
Dodds RM, Granic A, Davies K, Kirkwood TB, Jagger C, Sayer AA. Prevalence and incidence of sarcopenia in the very old: findings from the Newcastle 85+ Study. J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):229-237. doi: 10.1002/jcsm.12157.
Brown JC, Harhay MO, Harhay MN. Sarcopenia and mortality among a population-based sample of community-dwelling older adults. J Cachexia Sarcopenia Muscle. 2016 Jun;7(3):290-8. doi: 10.1002/jcsm.12073.
Kim JH, Lim S, Choi SH, et al. Sarcopenia: an independent predictor of mortality in community-dwelling older Kore-an men. J Gerontol A Biol Sci Med Sci. 2014 Oct;69(10):1244-52. doi: 10.1093/gerona/glu050.
Patel HP, Al-Shanti N, Davies LC, et al. Lean mass, muscle strength and gene expression in community dwelling older men: findings from the Hertfordshire sarcopenia study (HSS). Calcif Tissue Int. 2014 Oct;95(4):308-16. doi: 10.1007/s00223-014-9894-z.
Yamada M, Nishiguchi S, Fukutani N, et al. Prevalence of sarcopenia in community-dwelling Japanese older adults. J Am Med Dir Assoc. 2013 Dec;14(12):911-5. doi: 10.1016/j.jamda.2013.08.015.
Legrand D, Vaes B, Matheï C, Swine C, Degryse JM. The prevalence of sarcopenia in very old individuals according to the European consensusdefinition: insights from the BELFRAIL study. Age Ageing. 2013 Nov;42(6):727-34. doi: 10.1093/ageing/aft128.
Landi F, Liperoti R, Fusco D, et al. Prevalence and risk factors of sarcopenia among nursing home older residents. J Gerontol A Biol Sci Med Sci. 2012 Jan;67(1):48-55. doi: 10.1093/gerona/glr035.
Santo RCE, Fernandes KZ, Lora PS, Filippin LI, Xavier RM. Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2018 Oct;9(5):816-825. doi: 10.1002/jcsm.12320.
Tournadre A, Pereira B, Dutheil F, et al. Changes in body composition and metabolic profile during interleukin 6 inhibition in rheumatoid arthritis. J Cachexia Sarcopenia Muscle. 2017 Aug;8(4):639-646. doi: 10.1002/jcsm.12189.
Giles JT, Ling SM, Ferrucci L, et al. Abnormal body composition phenotypes in older rheumatoid arthritis patients: association with disease characteristics and pharmacotherapies. Arthritis Rheum. 2008 Jun 15;59(6):807-15. doi: 10.1002/art.23719.
Doğan SC, Hizmetli S, Hayta E, Kaptanoğlu E, Erselcan T, Güler E. Sarcopenia in women with rheumatoid arthritis. Eur J Rheumatol. 2015 Jun;2(2):57-61. doi: 10.5152/eurjrheum.2015.0038.
Munro R, Capell H. Prevalence of low body mass in rheumatoid arthritis: association with the acute phase response. Ann Rheum Dis. 1997 May;56(5):326-9. doi: 10.1136/ard.56.5.326.
Greenlund LJ, Nair KS. Sarcopenia-consequences mechanisms and potential therapies. Mech Ageing Dev. 2003 Mar;124(3):287-99.
Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002 May;57(5):M326-32.
Volpato S., Guralnik J.M., Ferrucci L. et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women: the women’s health and aging study. Circulation. 2001 Feb 20;103(7):947-53. doi: 10.1161/01.cir.103.7.947.
Ngeuleu A, Allali F, Medrare L, et al. Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors. Rheumatol Int. 2017 Jun; 37(6):1015-1020. doi: 10.1007/s00296-017-3665-x.
Torii M, Hashimoto M, Hanai A, et al. Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis. Mod Rheumatol. 2018 Sep 11:1-7. doi: 10.1080/14397595.2018.1510565.
Krajewska-Włodarczyk M. Sarcopenia in rheumatoid arthritis. Wiad Lek. 2016;69(3 pt 2):542-547. (in Polish).
Copyright (c) 2020 V.V. Povoroznyuk, N.I. Dzerovych, O.S. Ivanyk, T.A. Karasevska
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2020